Reneo Pharmaceuticals, Inc.

RPHM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$14,699-$15,390-$15,925-$15,332
Dep. & Amort.$204$212$212$590
Deferred Tax$0$0$0-$2,779
Stock-Based Comp.$2,961$2,908$2,745$1,144
Change in WC$0$0$0$10,562
Other Non-Cash-$1,503-$1,004-$1,037$2,272
Operating Cash Flow-$13,037-$13,274-$14,005-$3,543
Investing Activities
PP&E Inv.-$6-$13-$18-$25
Net Acquisitions$0$0$0$50
Inv. Purchases$0$0$0$108,949
Inv. Sales/Matur.$0$0$0-$169,075
Other Inv. Act.$0$0$0-$50
Investing Cash Flow-$6-$13-$18-$60,151
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$58,970
Stock Repurch.$0$0$0$4,403
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0-$77$115,943
Financing Cash Flow$0$0-$77$120,346
Forex Effect$0$0$0$0
Net Chg. in Cash-$13,043-$13,287-$14,100$74,791
Supplemental Information
Beg. Cash$83,374$96,661$110,761$35,970
End Cash$70,331$83,374$96,661$110,761
Free Cash Flow-$13,043-$13,287-$14,023-$3,568
Reneo Pharmaceuticals, Inc. (RPHM) Financial Statements & Key Stats | AlphaPilot